According to the World Health Organization (WHO), we are rapidly approaching a 'post-antibiotic' era. The knowledge gap about antibiotic resistance and room for progress is evident and unified combating strategies to mitigate the inadvertent trends of resistance seem to be lacking. Doxycycline remains a valuable antimicrobial agent by virtue of its potent microbiological profile, anti-inflammatory and immunomodulatory activity, and practical advantages like cost-effectiveness and ease of availability. Indian clinicians may like to consider doxycycline optimally for effective infection care. This may help Indian healthcare system, in defying the massive battle against anti-microbial resistance.
Dr. KK Aggarwal
President Heart Care Foundation of India and Group Editor in Chief MEDtalks
Dr. Shyam Sundar
Distinguished Professor, Infectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi
